Tag: Translational Pharmacology Award

Mridul Guleria | Pharmacology | Best Researcher Award

Published on by World Science Awards

Best Researcher Award

Mridul Guleria — Guru Nanak Dev University

Mridul Guleria
Affiliation Guru Nanak Dev University
Country India
Scopus ID 59174404600
Documents 14
Citations 84
h-index 4
Subject Area Pharmacology
Event World Science Awards
ORCID 0009-0008-5898-8134

Mridul Guleria is a researcher affiliated with Guru Nanak Dev University, India, whose documented scholarly profile is associated with the field of pharmacology. The available bibliometric record identifies 14 documents, 84 citations, and an h-index of 4 in Scopus. [1] These indicators provide a concise quantitative view of the researcher’s indexed scholarly output and citation visibility.

This academic recognition profile presents the researcher’s research background, contributions, publication record, research impact, and suitability for consideration for the Best Researcher Award associated with the World Science Awards. The assessment is framed using the supplied bibliographic information and publicly identifiable researcher records rather than unsupported claims of distinction.

Abstract

Mridul Guleria is affiliated with Guru Nanak Dev University and works within the subject area of pharmacology. The researcher’s indexed profile records 14 documents, 84 citations, and an h-index of 4. [1] The profile is additionally associated with an ORCID identifier, providing a persistent scholarly identity record. [2] On the basis of the supplied academic indicators, the Best Researcher Award profile highlights scholarly productivity, citation-based visibility, subject-area relevance, and participation in research activities within pharmacology.

Keywords

Mridul Guleria; Best Researcher Award; pharmacology; pharmaceutical research; Guru Nanak Dev University; research impact; scholarly publications; citation analysis; Scopus; ORCID; World Science Awards.

Introduction

Pharmacology is a multidisciplinary area concerned with the study of drugs, their biological effects, mechanisms of action, therapeutic applications, and interactions with living systems. Research in this field contributes to the broader development and evaluation of pharmacological knowledge and can intersect with pharmaceutical sciences, biomedical research, toxicology, and related disciplines.

Within an academic recognition framework, researcher evaluation may consider several dimensions, including research productivity, publication activity, citation performance, subject relevance, originality, scholarly contribution, and broader research influence. Bibliometric databases such as Scopus can provide quantitative indicators for assessing indexed research output, while ORCID provides a persistent identifier that helps distinguish researchers and connect scholarly works with their authors. [1] [2]

Research Profile

The supplied research profile identifies Mridul Guleria as being affiliated with Guru Nanak Dev University in India and specializing in pharmacology.

These figures should be interpreted as a snapshot of the indexed research record and may change as databases update publication and citation information. [1]

Research Contributions

Mridul Guleria’s documented research specialization is pharmacology. The available record supports recognition of research activity within this subject area, while the supplied bibliometric indicators provide evidence of an established indexed publication and citation record. [1]

For academic evaluation purposes, the contribution profile can be considered across the following dimensions:

  • Subject-area engagement: Research activity is associated with pharmacology, a field relevant to drug research and biomedical science.
  • Scholarly productivity: Fourteen documents are recorded in the supplied Scopus profile.
  • Citation visibility: The supplied profile records 84 citations, indicating that indexed publications have received measurable scholarly referencing.
  • Research continuity: The presence of multiple indexed documents provides evidence of continuing scholarly publication activity.
  • Researcher identification: The association of Scopus and ORCID identifiers supports clearer attribution of scholarly work to the researcher. [1] [2]

Publications

The supplied Scopus record indicates 14 indexed documents associated with Mridul Guleria. [1] The available input does not provide a complete publication bibliography, individual article titles, journal names, publication dates, citation distributions, or DOI identifiers. Accordingly, no specific publication titles or DOI values are attributed here without bibliographic verification.

For a complete publication assessment, the Scopus author record and the researcher’s ORCID profile can be consulted to identify publications, author associations, and persistent scholarly records. [1] [2]

Research Impact

The supplied Scopus indicators show 84 citations across 14 documents and an h-index of 4. [1] These measures provide quantitative evidence of citation activity and scholarly visibility within the indexed research literature.

Citation counts and h-index values are useful indicators but should not be interpreted independently of publication context, career stage, discipline, authorship patterns, journal characteristics, or the nature of individual contributions. A balanced assessment of research impact therefore benefits from combining bibliometric information with qualitative evaluation of research originality, methodological quality, relevance, collaboration, and contribution to the field.

The presence of an ORCID identifier further supports persistent researcher identification and can facilitate the reliable association of scholarly outputs with the appropriate researcher. [2]

Award Suitability

The Best Researcher Award profile for Mridul Guleria is supported by the supplied evidence of academic affiliation, subject-area specialization, indexed publication activity, and citation performance. The World Science Awards provides the event context for this recognition. [3]

Based on the available information, relevant evaluation dimensions include:

  • Academic relevance: The researcher’s specialization in pharmacology aligns with a recognized scientific and biomedical research domain.
  • Publication record: Fourteen Scopus-indexed documents demonstrate measurable scholarly productivity. [1]
  • Citation performance: Eighty-four citations provide an observable indicator of scholarly attention to the indexed research output. [1]
  • h-index: An h-index of 4 provides an additional quantitative measure of citation distribution across the researcher’s indexed publications. [1]
  • Researcher identity: The availability of both Scopus and ORCID identifiers supports transparent scholarly attribution. [1] [2]

Taken together, these documented indicators provide a reasonable academic basis for consideration under a Best Researcher Award framework. Final award decisions, however, should be based on the official evaluation methodology, verified publication records, research quality, originality, and other criteria established by the awarding organization. [3]

Conclusion

Mridul Guleria is an India-based researcher affiliated with Guru Nanak Dev University whose documented research area is pharmacology. The supplied scholarly profile records 14 documents, 84 citations, and an h-index of 4 in Scopus, alongside an ORCID identifier that provides a persistent researcher identity. [1] [2]

The available evidence demonstrates measurable research productivity and citation visibility and provides a documented foundation for consideration for the Best Researcher Award at the World Science Awards. [3] Any final recognition should be determined through independent verification and the formal assessment criteria of the awarding body.

References

  1. Elsevier. (n.d.). Scopus author details: Mridul Guleria, Author ID 59174404600. Scopus.
    https://www.scopus.com/pages/authors/59174404600
  2. ORCID. (n.d.). ORCID record: Mridul Guleria, ORCID iD 0009-0008-5898-8134. ORCID.
    https://orcid.org/0009-0008-5898-8134
  3. World Science Awards. (n.d.). World Science Awards.
    https://worldscienceawards.com/

Mohammad Seyedabadi | Pharmacology | Best Researcher Award

Published on by World Science Awards

Best Researcher Award

Mohammad Seyedabadi, Mazandaran University of Medical Sciences
Mohammad Seyedabadi
Affiliation Mazandaran University of Medical Sciences
Country Iran
Scopus ID 24460920400
Documents 86
Citations 2,110
h-index 25
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-0044-8270

Mohammad Seyedabadi is a researcher affiliated with Mazandaran University of Medical Sciences in Iran, with a documented research specialization in pharmacology. The academic recognition presented in this article is the Best Researcher Award associated with the World Science Awards. The supplied research profile records 86 documents, 2,110 citations, and an h-index of 25. These bibliometric indicators provide a quantitative overview of the documented research record and are presented as profile information rather than as independent measures of scientific quality. Pharmacology encompasses the study of drugs, their mechanisms of action, therapeutic effects, adverse effects, and interactions with biological systems. [1][2]

Abstract

This article presents an academic recognition profile for Mohammad SEYEDABADI of Mazandaran University of Medical Sciences, Iran, in connection with the Best Researcher Award under the World Science Awards. The documented research subject is pharmacology, a biomedical discipline concerned with the properties, mechanisms, therapeutic applications, and safety of drugs and other bioactive substances. [1][2] The supplied bibliometric record identifies 86 documents, 2,110 citations, and an h-index of 25. These indicators suggest a substantial indexed research record within the supplied profile, while their interpretation should account for publication history, disciplinary citation practices, collaboration patterns, and the characteristics of individual publications. The award suitability discussion therefore considers the documented research specialization, publication volume, citation activity, and overall bibliometric profile without treating these measures as substitutes for qualitative assessment.

Keywords

  • Pharmacology
  • Drug discovery
  • Pharmacological research
  • Therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Biomedical science
  • Research impact

Introduction

Pharmacology is a central biomedical discipline that examines how chemical substances interact with living systems. It includes the study of drug mechanisms, pharmacodynamics, pharmacokinetics, therapeutic efficacy, adverse effects, and interactions. [1][2] Pharmacological research provides a scientific basis for understanding the actions of medicines and for supporting the development and evaluation of therapeutic interventions.

Modern pharmacology is closely connected with molecular biology, physiology, biochemistry, toxicology, medicinal chemistry, and clinical medicine. Research may range from investigations of molecular targets and signaling pathways to experimental evaluation of candidate compounds and clinical studies of therapeutic responses. The integration of these disciplines has contributed to the development of more selective treatments and improved understanding of drug response variability. [2][3]

Within this scientific context, Mohammad SEYEDABADI is identified in the supplied profile as a pharmacology researcher affiliated with Mazandaran University of Medical Sciences. The reported record of 86 documents, 2,110 citations, and an h-index of 25 provides a quantitative description of the indexed research profile. Further conclusions regarding specific scientific discoveries or therapeutic applications require examination of the underlying publications and verified research outputs.

Research Profile

Mohammad SEYEDABADI is affiliated with Mazandaran University of Medical Sciences in Iran. The supplied subject classification is pharmacology, placing the profile within the broader biomedical and pharmaceutical sciences. The reported combination of publication output and citation activity provides a bibliometric overview of the researcher’s indexed scholarly record. An h-index of 25 indicates that, within the supplied record, at least 25 publications have received at least 25 citations each, subject to the accuracy and coverage of the underlying database record. Bibliometric indicators should nevertheless be interpreted in their disciplinary and temporal context.

Research Contributions

The documented specialization of Mohammad SEYEDABADI is pharmacology. As a broad research field, pharmacology contributes to the scientific understanding of how therapeutic agents interact with biological targets and how those interactions influence physiological and pathological processes. [1][2] Pharmacological investigations may address molecular mechanisms, drug efficacy, safety, metabolism, therapeutic response, and interactions between medicines.

The supplied profile does not identify specific publication titles, experimental models, molecular targets, compounds, therapeutic areas, or clinical outcomes. Therefore, specific technical contributions are not attributed to the researcher beyond the documented subject classification. A detailed assessment of individual contributions would require review of the researcher’s publications and associated bibliographic records.

  • Research activity within the field of pharmacology.
  • Contribution to the indexed biomedical literature through a reported record of 86 documents.
  • Documented citation activity of 2,110 citations within the supplied profile.
  • A reported h-index of 25 as a measure of citation distribution within the indexed record.

These indicators describe scholarly output and visibility but do not by themselves establish the novelty, methodological quality, clinical relevance, or translational significance of individual studies.

Publications

The supplied research profile reports 86 documents and 2,110 citations. It does not provide a complete publication list, individual publication titles, journal information, publication dates, authorship details, or DOI identifiers for the researcher’s works. Consequently, no specific publication metadata are inferred in this article. For authoritative publication-level information, the researcher’s Scopus author record should be consulted directly. Database coverage, author disambiguation, citation counts, and document totals may change as indexing systems are updated.

Research Impact

The supplied profile reports 2,110 citations across 86 documents and an h-index of 25. These figures indicate that the indexed research record has received substantial citation activity within the reported database profile. Citation counts can provide evidence of scholarly visibility, although they do not by themselves measure research quality, reproducibility, clinical importance, or societal impact.

In pharmacology, research impact may arise through advances in understanding drug mechanisms, identification of biological targets, evaluation of therapeutic efficacy, characterization of safety profiles, or contributions to translational and clinical research. [1][2][3] The significance of a particular contribution therefore depends on the scientific question addressed, methodological rigor, reproducibility, and subsequent use of the findings.

For this profile, the available evidence supports a quantitative description of research impact based on document and citation counts and the reported h-index. Determining broader scientific or clinical impact would require additional evidence, such as highly cited publications, clinical translation, patents, guidelines, collaborations, or documented changes in research or healthcare practice.

Award Suitability

The Best Researcher Award profile is thematically aligned with Mohammad SEYEDABADI’s documented research specialization in pharmacology and the supplied record of scholarly output. The profile reports 86 documents, 2,110 citations, and an h-index of 25, providing several quantitative indicators that may be relevant when evaluating research activity and scholarly visibility.

The researcher is affiliated with Mazandaran University of Medical Sciences and is identified through Scopus Author ID 24460920400 and ORCID 0000-0003-0044-8270. These persistent identifiers provide mechanisms for distinguishing the researcher’s scholarly record and supporting bibliographic verification. On the basis of the supplied information, the profile provides a clear research-area match and a documented scholarly record that can support consideration for an award recognizing research activity. A formal award decision should additionally consider the official eligibility requirements, originality of research, methodological quality, peer-reviewed contributions, field-specific significance, and any qualitative criteria established by the World Science Awards.

Conclusion

Mohammad SEYEDABADI is identified in the supplied academic profile as a pharmacology researcher affiliated with Mazandaran University of Medical Sciences in Iran. The reported research record includes 86 documents, 2,110 citations, and an h-index of 25. These indicators provide a quantitative representation of the researcher’s indexed scholarly activity and citation visibility.

Pharmacology is an established biomedical field with direct relevance to drug mechanisms, therapeutic development, safety assessment, and clinical science. [1][2] The documented research specialization and bibliometric record provide a reasonable academic basis for an award profile focused on research achievement, while a comprehensive assessment of scientific distinction should incorporate publication-level evidence and qualitative evaluation in accordance with the applicable award criteria.

References

  1. Katzung, B. G., Vanderah, T. W. Basic & Clinical Pharmacology. McGraw Hill. This reference provides a general foundation for pharmacodynamics, pharmacokinetics, drug mechanisms, and therapeutic pharmacology.
  2. Brunton, L. L., Hilal-Dandan, R., Knollmann, B. C., eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw Hill. The text provides established principles concerning drug actions, therapeutic effects, mechanisms, and adverse reactions.
  3. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., Henderson, G. Rang & Dale’s Pharmacology. Elsevier. This reference covers pharmacological mechanisms and the relationship between drugs and biological systems.
  4. Scopus. Scopus Author Profile: Mohammad SEYEDABADI, Author ID 24460920400. The supplied profile identifies the researcher and reports the bibliometric information used in this article.
  5. ORCID. ORCID Record: Mohammad SEYEDABADI, ORCID 0000-0003-0044-8270. The persistent identifier is supplied as the researcher’s ORCID record.

The DOI references above are provided where applicable to support established scholarly literature. The researcher-specific bibliometric values in this article are based on the supplied profile information and should be checked against the current database records for the latest values.

Shakir Siddiqui | Pharmacology | Research Excellence Award

Published on by World Science Awards

Research Excellence Award

Shakir Siddiqui
Saras College of Pharmacy
Shakir Siddiqui
Affiliation Saras College of Pharmacy
Country India
Scopus ID 60706630600
Documents 2
Citations 1
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0009-0008-5328-8606

The Research Excellence Award recognizes scholarly contributions that demonstrate commitment to scientific research, academic development, and the advancement of knowledge within a defined discipline. Shakir Siddiqui, affiliated with Saras College of Pharmacy in India, has an emerging research profile in pharmacology supported by indexed scholarly publications and documented citation activity. The available bibliometric record provides an objective basis for describing his participation in the scientific literature.[1]

Abstract

Shakir Siddiqui is a researcher associated with Saras College of Pharmacy whose academic subject area is pharmacology. His available Scopus record comprises two indexed documents, one citation, and an h-index of one. These indicators represent an early-stage scholarly profile and demonstrate participation in formal scientific publication. Research in pharmacology contributes to the understanding of drugs, therapeutic mechanisms, safety, efficacy, and their applications in healthcare.[1][2]

Keywords

  • Pharmacology
  • Pharmaceutical Sciences
  • Drug Research
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Excellence
  • Health Sciences

Introduction

Pharmacology is a core biomedical discipline concerned with the study of medicines and their interactions with biological systems. It encompasses the mechanisms of drug action, pharmacokinetics, pharmacodynamics, therapeutic applications, adverse effects, and the development of evidence-based approaches to medication use. Research in this area supports the discovery and evaluation of treatments and contributes to improved healthcare practice.[2]

Research Profile

The available Scopus information identifies Shakir Siddiqui under the subject area of Pharmacology and records two indexed documents, one citation, and an h-index of one. These bibliometric measures indicate participation in scholarly research and provide a quantitative snapshot of the researcher’s current publication and citation activity.[1]

  • Affiliation: Saras College of Pharmacy.
  • Country: India.
  • Primary subject area: Pharmacology.
  • Scopus-indexed documents: 2.
  • Citations: 1.
  • h-index: 1.

Research Contributions

The researcher’s documented scholarly activity is situated within pharmacology and the broader pharmaceutical sciences. Research in these fields supports scientific understanding of therapeutic agents, biological responses, drug safety, and clinical applications. Contributions through peer-reviewed publication provide mechanisms for communicating findings to the wider scientific community and for supporting subsequent research.[2][3]

Publications

Shakir Siddiqui has two documents indexed in Scopus according to the supplied researcher profile. The indexed publication record represents scholarly dissemination within an internationally recognized bibliographic database. Continued publication and collaboration can provide opportunities for further development of research visibility and contribution to pharmacological literature.[1]

  • Indexed scholarly documents.
  • Pharmacology-related research.
  • Scientific communication through academic publications.
  • Participation in pharmaceutical and biomedical research.

Research Impact

Research impact can be considered through multiple dimensions, including publication quality, citation activity, methodological contribution, collaboration, and relevance to scientific or clinical practice. The current bibliometric profile records one citation and an h-index of one, providing measurable evidence of scholarly uptake within the indexed literature. These metrics should be interpreted in the context of publication volume and the researcher’s stage of academic development.[1]

Award Suitability

Based on the supplied academic information, Shakir Siddiqui demonstrates scholarly engagement in pharmacology through indexed research publications and documented citation activity. These characteristics may be considered as part of an award evaluation focused on research excellence. The World Science Awards may assess nominees using broader criteria such as research quality, originality, professional contribution, publication record, and potential impact; therefore, bibliometric indicators should be considered alongside qualitative evidence when evaluating award suitability.[1][4]

Conclusion

Shakir Siddiqui has established an emerging academic profile in pharmacology through participation in indexed scientific research. The available record of two Scopus documents, one citation, and an h-index of one provides a concise quantitative representation of his current scholarly activity. His affiliation with Saras College of Pharmacy places his research within the academic and pharmaceutical sciences environment, where continued investigation and publication can contribute to the development of evidence-based knowledge.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Shakir Siddiqui, Author ID 60706630600. Scopus.
    https://www.scopus.com/pages/authors/60706630600
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw Hill.
    DOI: https://doi.org/10.1036/9781259588331
  3. Katzung, B. G., Vanderah, T. W. Basic & Clinical Pharmacology. McGraw Hill.
    DOI: https://doi.org/10.1036/9781260463325
  4. World Science Awards. (n.d.). Official Award Information.
    https://worldscienceawards.com/

Liang Zhou | Clinical Pharmacology | Best Researcher Award

Published on by World Science Awards

Ms. Liang Zhou | Clinical Pharmacology | Best Researcher Award

Shanghai Henlius Biotech Inc., China

Ms. Liang Zhou is a distinguished clinical pharmacology professional with extensive experience in oncology drug development, pharmacokinetics, and translational research. She earned her Master’s degree in Drug Metabolism and Pharmacokinetics from the China Pharmaceutical University in 2008, which laid the foundation for her successful career in pharmaceutical sciences. Over the years, she has held progressive positions in leading global and Chinese organizations, including Associate Senior Scientist at Wuxi Apptec, Demo Chemist at Thermo Fisher Shanghai, Associate Director of Clinical Pharmacology at Mosim, and currently serves as the Senior Director of Clinical Pharmacology at Shanghai Henlius Biotech, Inc. since 2021. In these roles, she has contributed to more than 11 significant clinical trial programs across China, Australia, Japan, Europe, and the United States, with a strong focus on first-in-human (FIH) trials, PK/PD analysis, and oncology indications such as breast cancer, lymphoma, AML, NSCLC, gastric and pancreatic cancers, among others. Her research interests center on oncology drug development, dose exploration studies, biomarker integration, and regulatory science to accelerate access to novel therapies. With 23 academic documents, 91 citations, and an h-index of 4, Ms. Zhou demonstrates measurable scholarly impact, supported by her memberships in professional societies such as the Chinese Society of Clinical Oncology (CSCO). She has also enhanced her expertise through specialized training in GCP compliance, oncology drug development, and advanced pharmacometrics including R-language applications. Her skills encompass pharmacokinetic modeling, clinical trial design, regulatory submission, and team leadership, which collectively position her as a key figure in clinical pharmacology. Recognized for her contributions to cancer research and drug development, she continues to build a strong professional profile with the potential for international recognition. In conclusion, Ms. Liang Zhou’s blend of academic excellence, clinical research leadership, and commitment to advancing oncology therapeutics makes her a deserving candidate for prestigious awards and a driving force in global biomedical innovation.

Profile: Scopus

Featured Publications

Li, X., Zhang, Y., Wang, J., Chen, H., Zhou, L., Liu, M., … [et al.]. (2023). HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: An open-label, dose-escalation, phase 1 trial.(5)

Khushi Quadri | Pharmacology | Best Researcher Award

Published on by World Science Awards

Ms. Khushi Quadri | Pharmacology | Best Researcher Award

Research Scholar at SGT COLLEGE OF PHARMACY, India

Khushi Quadri is a passionate and driven researcher in the field of pharmaceutics, with a strong focus on nanotechnology, drug delivery systems, and biomedical applications. She has excelled academically, achieving an impressive 88.6% in her Master’s program at SGT University, Gurugram. Khushi has contributed extensively to the scientific community through publications in reputed journals such as Elsevier and iLiver. Her research spans diverse areas, including neurological disease treatments, biosensors, and eco-friendly nanomaterials. She has presented her work at several national and international conferences, showcasing her ability to effectively communicate complex scientific ideas. Khushi’s dedication to innovation and excellence has earned her recognition in competitions and tech fests. Alongside her academic and research pursuits, she has developed skills in teamwork, communication, and adaptability, making her a well-rounded professional.

Professional Profile

Education

Khushi Quadri has a robust academic foundation in pharmacy and pharmaceutics. She is currently completing her Master’s degree in Pharmaceutics at SGT University, Gurugram (2022-2024), where she has maintained an exceptional 88.6% score. Prior to this, she earned her Bachelor’s degree in Pharmacy from B.S. Anangpuria Institute of Pharmacy, Faridabad, achieving 75.7%. Her earlier education includes a solid performance in Class XII and Class X from Kalka Public School, Alaknanda, with scores of 86.8% and 76%, respectively. This strong educational background reflects her consistency and commitment to academic excellence.

Professional Experience

Khushi has actively engaged in professional academic and research activities. Her experience includes presenting posters at multiple international and national conferences, focusing on innovative topics like eco-friendly nanoparticles, biosensors, and drug delivery systems. She has also participated in numerous workshops, gaining hands-on knowledge in areas like tablet compression, coating techniques, and spectroscopy. Through these engagements, she has honed her research and presentation skills, enabling her to effectively contribute to the scientific community.

Research Interests

Khushi’s research interests lie at the intersection of pharmaceutics, nanotechnology, and biomedical sciences. She is particularly focused on green synthesis of nanoparticles for drug delivery and therapeutic applications, including neurological diseases and cancer treatment. Her work also explores the role of inorganic nanoparticles in water purification, biosensors, and antimicrobial therapies. Her commitment to sustainable research is evident in her studies on eco-friendly materials and their environmental impact.

Research Skills

Khushi Quadri possesses a diverse skill set that complements her research activities. She is proficient in designing and optimizing green synthesis techniques for nanoparticles and evaluating their biomedical applications. Her expertise extends to spectroscopic techniques, including FTIR and UV spectroscopy, and she has a strong grasp of Microsoft Excel and Word for data analysis and documentation. Additionally, her collaborative and adaptable nature allows her to effectively work in multidisciplinary teams, contributing innovative solutions to complex research challenges.

Awards and Honors

Khushi has been recognized for her academic and research excellence through several awards and honors. Notably, she secured 3rd rank in the Synergy Tech Fest 2023 for her project on eco-friendly mosquito repellents. She has also participated in various competitive events, including national conferences and debates, reflecting her proactive engagement with the academic community. Certificates of appreciation for her achievements in CBSE board exams and employability skills further underscore her dedication to personal and professional growth.

Conclusion 🎯

Khushi Quadri has demonstrated commendable achievements in academic performance, research, and conference participation, making her a strong candidate for early-career researcher recognition. However, for a Best Researcher Award, areas like deep specialization, innovation, international collaboration, and leadership experience may need further development.

Publication Top Notes

  1. New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products
    • Authors: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam
    • Journal/Source: iLIVER
    • Year: 2024
    • Citation: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam, “New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products,” iLIVER, vol. 100131, 2024.
  2. A New Era of Nanotechnology Applied in Neurological Disease Treatment
    • Authors: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar, “A New Era of Nanotechnology Applied in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.
  3. Potential Role of Probiotics in Neurological Disease Treatment
    • Authors: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat, “Potential Role of Probiotics in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.

 

Seval Bulut | Pharmacology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Seval Bulut | Pharmacology | Best Researcher Award

Erzincan Binali Yıldırım University at Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

Dr. Seval Bulut is an accomplished researcher and Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University in Turkey. With an extensive background in medicine and pharmacology, her research focuses on drug safety, therapeutic interventions, and protective effects of natural extracts on organ function. Dr. Bulut’s prolific work includes 45 research articles published in leading SSCI and SCIE journals, where she has explored biochemical and histopathological mechanisms underlying drug-induced toxicity and protective pharmacological agents. Her studies span organ systems and conditions such as hepatotoxicity, renal damage, reproductive health, and ischemic syndrome, showcasing a robust interdisciplinary approach. Dr. Bulut has contributed to advancing pharmacological research with her findings on natural compounds and coenzyme Q10’s efficacy in mitigating organ dysfunction. Her academic influence extends through her roles as a physician and educator, mentoring emerging researchers in pharmacology. Dr. Bulut’s dedication to drug safety and therapeutic research has not only bolstered her professional reputation but also holds promise for improving patient care and drug efficacy in clinical settings.

Professional Profile

Education

Dr. Seval Bulut’s educational background exemplifies her dedication to the fields of medicine and pharmacology. She earned her MD from Atatürk University Faculty of Medicine in 2001, embarking on her journey as a physician committed to improving patient outcomes. Dr. Bulut later transitioned to academia, pursuing a doctoral program at Erzincan Binali Yıldırım University’s Institute of Health Sciences, Department of Medical Pharmacology. In 2024, she completed her PhD with a thesis titled “The Effect of Liv-52 on Favipiravir-Induced Hepatotoxicity in Rats: Biochemical and Histopathological Evaluation,” demonstrating her keen focus on pharmacology, particularly in drug-induced toxicity. This advanced education has equipped Dr. Bulut with a strong foundation in both clinical and research aspects of pharmacology, enabling her to investigate the biochemical mechanisms of drug interactions and develop therapeutic strategies for organ protection. Her academic journey reflects a consistent focus on integrating medical practice with pharmacological research to address real-world health challenges.

Professional Experience

Dr. Bulut’s professional experience is rooted in her dual roles as a clinician and researcher. She initially practiced medicine across various health institutions from 2001 to 2010, gaining valuable hands-on experience that provided her with a comprehensive understanding of patient care. Transitioning to a Family Physician role between 2010 and 2024, she developed a strong patient-focused perspective, which later became integral to her research approach. Currently, Dr. Bulut serves as an Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University. In this academic role, she has combined her clinical insights with research expertise, conducting studies on pharmacological interventions to protect against drug-induced organ damage. Her extensive background in clinical medicine complements her current research endeavors, where she investigates the biochemical and histopathological mechanisms of pharmacological agents. This blend of professional experience positions Dr. Bulut as a knowledgeable researcher who brings both theoretical and practical insights to her field.

Research Interests

Dr. Seval Bulut’s research interests lie at the intersection of pharmacology, toxicology, and therapeutic interventions. She is particularly focused on understanding drug-induced toxicity and the protective effects of natural compounds on organ systems. Her work has centered on evaluating the biochemical and histopathological mechanisms of various pharmacological agents, including the impact of drugs such as favipiravir on liver health. Dr. Bulut’s studies also explore natural compounds like coenzyme Q10 and cinnamon extract for their potential to mitigate organ dysfunction, particularly in kidney and liver applications. Additionally, she has examined the effects of pharmaceutical compounds on reproductive health, as well as protective pharmacological strategies for conditions such as ischemic ocular syndrome. Her research contributes to improving drug safety and efficacy, providing insights that could lead to safer clinical applications and therapeutic innovations. Through her interdisciplinary research, Dr. Bulut aims to enhance the understanding of pharmacodynamics and pharmacokinetics in therapeutic contexts.

Research Skills

Dr. Seval Bulut has developed a broad set of research skills essential to her pharmacological studies. She is adept in designing and conducting in vivo experiments, specifically using animal models to assess drug efficacy and toxicity. Her skills in biochemical and histopathological analysis are evidenced in her research on drug-induced organ toxicity, where she utilizes various biochemical markers and staining techniques to evaluate cellular and tissue changes. Dr. Bulut is also proficient in data analysis and interpretation, crucial for her work in pharmacology and toxicology, where she frequently analyzes complex datasets to draw meaningful conclusions about drug interactions and therapeutic effects. Additionally, she is skilled in the ethical and methodological aspects of animal research, ensuring that her studies meet rigorous scientific standards. Her collaborative skills are reflected in her ability to work alongside other professionals, contributing to a multidisciplinary approach in her studies on pharmacological agents and natural compounds.

Awards and Honors

Dr. Seval Bulut’s academic and professional achievements have earned her recognition in the scientific community. Her prolific publication record includes 45 research articles indexed in SSCI and SCIE, which demonstrates her commitment to advancing pharmacological research. These publications span influential journals, highlighting her research’s impact and relevance in the field. Dr. Bulut’s focus on drug safety, natural therapeutics, and organ protection has led to invitations to present her findings at international congresses, further establishing her as a respected voice in pharmacology. Additionally, her progression from a practicing physician to a PhD-holder and Assistant Professor in a highly specialized research area reflects her dedication to both medical practice and academia. Although specific awards are not listed, her consistent scholarly contributions and active research agenda signal her as a promising candidate for future awards recognizing excellence in research and contributions to pharmacology. Her work holds significant implications for clinical safety and therapeutic advancements, which are critical areas of modern medical research.

Conclusion

Dr. Seval Bulut is a strong candidate for the Best Researcher Award due to her significant contributions to pharmacological research and her commitment to addressing drug safety and therapeutic efficacy. Her expertise, publication volume, and applied research focus on organ protection and biochemical evaluation highlight her as an impactful researcher. Continued emphasis on international collaboration, active conference participation, and funding pursuit could further elevate her profile and ensure sustained research advancements.

Publications Top Notes

  1. Title: Effect of ethyl acetate extract from Usnea longissima on chemotherapy-associated multiple organ dysfunction in rats
    Authors: Bingul, E., Bulut, S., Mammadov, R., Suleyman, H., Mendil, A.S.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 181
    Article ID: 117636
  2. Title: The hormonal mechanism of the effects of meperidine, sertraline, tianeptine, and their combinations on reproductive functions in female rats
    Authors: Yilmaz, B.K., Suleyman, Z., Suleyman, B., Coban, T.A., Suleyman, H.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 178
    Article ID: 117160
  3. Title: Lacidipine, thiamine pyrophosphate and their combination on the ocular ischemic syndrome induced by bilateral common carotid artery ligation
    Authors: Cicek, I., Somuncu, A.M., Altuner, D., Tastan, T.B., Suleyman, H.
    Journal: International Journal of Ophthalmology
    Year: 2024
    Volume: 17, Issue 5
    Pages: 815–821
  4. Title: Effects of adenosine triphosphate, Lacidipine, and Benidipine on 5-fluorouracil-induced kidney damage in rats
    Authors: Dagel, T., Altuner, D., Suleyman, B., Gulaboglu, M., Suleyman, H.
    Journal: European Review for Medical and Pharmacological Sciences
    Year: 2024
    Volume: 28, Issue 6
    Pages: 2538–2549
  5. Title: Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats
    Authors: Ekici, O., Gul, A., Keskin, E., Gunay, M., Suleyman, H.
    Journal: Clinical and Experimental Nephrology
    Year: 2024
  6. Title: Protective effects of thiamine pyrophosphate and cinnamon against oxidative liver damage induced by an isoniazid and rifampicin combination in rats
    Authors: Yeter, B., Mammadov, R., Koc, Z., Gulaboglu, M., Suleyman, H.
    Journal: Investigacion Clinica (Venezuela)
    Year: 2024
    Volume: 65, Issue 3
    Pages: 321–334
  7. Title: Protective effect of cinnamon extract against cobalt-induced multiple organ damage in rats
    Authors: Isik, B., Suleyman, B., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Frontiers in Pharmacology
    Year: 2024
    Volume: 15
    Article ID: 1384181
  8. Title: Role of L-, N- and T-type calcium channels in achieving maximum analgesic and minimum toxic effect of tramadol
    Authors: Yilmaz, M., Suleyman, B., Mammadov, R., Coskun, R., Suleyman, H.
    Journal: Acta Poloniae Pharmaceutica – Drug Research
    Year: 2024
    Volume: 81, Issue 1
    Pages: 135–143
  9. Title: Protective Effect of Ramipril Against Oxidant and Proinflammatory Cytokine Damage Induced by Ischemia-Reperfusion in Ovarian Tissue in Rats
    Authors: Ulug, P., Nayki, U., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Transplantation Proceedings
    Year: 2024
    Volume: 56, Issue 1
    Pages: 215–222
  10. Title: Effect of pycnogenol on ischemia/reperfusion-induced oxidative and inflammatory damage in the ovaries of rats
    Authors: Dinc, K., Kiremitli, S., Suleyman, B., Altuner, D., Suleyman, H.
    Journal: Tropical Journal of Pharmaceutical Research
    Year: 2023
    Volume: 22, Issue 11
    Pages: 2297–2303

 

 

Moein Masjedi | Pharmacology | Best Researcher Award

Published on by World Science Awards

Moein Masjedi | Pharmacology | Best Researcher Award

Moein Masjedi, DarooSazan Sorena Exir Pharmaceutical Company, Iran.

Moein Masjedi is a dedicated researcher in the field of pharmacology, recognized for his innovative contributions to drug development and therapeutic strategies. With a strong academic background and a commitment to advancing scientific knowledge, he has published numerous influential papers that address critical challenges in the field. Awarded the Best Researcher Award for his outstanding research impact, Moein continues to inspire peers and students through his passion for improving health outcomes and enhancing patient care.

Profile:

Education

Moein Masjedi earned his Doctor of Pharmacy degree from Shiraz University of Medical Sciences in Shiraz, Fars, Iran, where he completed his thesis on the drug utilization evaluation of captopril in two coronary care units at Namazi Hospital, achieving a GPA of 15.64 out of 20. He then pursued a Ph.D. in Pharmaceutics at the same institution, focusing on the nose-to-brain delivery of Sumatriptan using chitosan nanoparticles and nanostructured lipid carriers (NLCs), and graduated with a GPA of 17.83 out of 20.

 

Skills 

Moein Masjedi possesses a diverse skill set that enhances his effectiveness as a researcher and collaborator. He excels in strong and collaborative communication, fostering teamwork and idea exchange. His creativity in problem-solving and critical thinking enables him to tackle complex challenges in pharmacology. Demonstrating leadership qualities, he effectively manages projects while prioritizing time management to meet deadlines. Additionally, he is skilled in structural scientific writing and proofreading, ensuring clarity and precision in his research publications. Beyond academia, Moein has a passion for art interpretation and enjoys swimming and yoga, which contribute to his overall well-being and work-life balance.

Areas of Interest:

Moein Masjedi’s research interests focus on innovative drug delivery systems and formulation design. He is particularly passionate about nanoparticulate drug delivery and the optimization of formulations for pulmonary, ocular, topical, and transdermal applications. His work includes designing novel drug delivery systems targeting specific sites such as the pulmonary system, colon, brain, and hair follicles. He explores the use of nanovesicles, lipid, and polymeric nanoparticles for both therapeutic and cosmetic applications. Additionally, Moein is interested in D-optimal optimization of aesthetic formulations and the development of stimuli-responsive or smart polymers for drug delivery. He employs Design of Experiments (DoE) methodologies to optimize formulations and is also engaged in the innovative 3D printing of pharmaceutical dosage forms, aiming to advance the field of pharmaceutics.

Publication Top Notes

  1. Masjedi, M., Izadi, Y., Montahaei, T., Mohammadi, R., Helforoush, M. A., & Rohani Rad, K. (2024). An illustrated review on herbal medicine used for the treatment of female infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology, 0(0).
  2. Dahri, M., Beheshtizadeh, N., Seyedpour, N., Nakhostin-Ansari, A., Aghajani, F., Seyedpour, S., Masjedi, M., Farjadian, F., Maleki, R., & Adibkia, K. (2023). Biomaterial-based delivery platforms for transdermal immunotherapy. Biomedicine & Pharmacotherapy, 165, 115048.
  3. Rezaie, F., Farshbaf, M., Dahri, M., Masjedi, M., Maleki, R., Amini, F., Wirth, J., Moharamzadeh, K., Weber, F. E., & Tayebi, L. (2023). 3D printing of dental prostheses: Current and emerging applications. Journal of Composites Science, 7(2), 80.
  4. Masjedi, M., Montahaei, T., Sharafi, Z., & Jalali, A. (2022). Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy. Journal of Drug Delivery Science and Technology, 103184.
  5. Masjedi, M., & Solhjoo, A. (2022). Does trigonelline help skin tone? Molecular docking studies of trigonelline on the human tyrosinase, formulation, optimization and characterization of an emulgel containing Trigonella foenum‐graecum L. fenugreek standardized hydroalcoholic extract. Journal of Cosmetic Dermatology.
  6. Masjedi, M., & Namazi, S. (2020). Drug utilization evaluation (DUE) of captopril in two coronary care units (CCU) of Namazi Hospital, Shiraz, Iran.
  7. Masjedi, M., & Montahaei, T. (2020). An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications. Journal of Drug Delivery Science and Technology, 102234.
  8. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi-Samani, S. (2020). Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: Preparation, in vitro characterization, and (neuro-) pharmacokinetic evaluations. Journal of Drug Delivery Science and Technology, 102179.
  9. Ziaei, A., Davoodian, P., Dadvand, H., Safa, O., Hassanipour, S., Omidi, M., Masjedi, M., Mahmoudikia, F., Rafiee, B., & Fathalipour, M. (2020). Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 1-3.
  10. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi‐Samani, S. (2020). Nose‐to‐brain delivery of sumatriptan‐loaded nanostructured lipid carriers: Preparation, optimization, characterization, and pharmacokinetic evaluation. Journal of Pharmacy and Pharmacology, 72(10), 1341-1351.